Pioneering Efforts in TeleRobotic Surgery Focus of Webcast Symposium on June 20th
June 10 2020 - 9:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced the hosting of an Inaugural Symposium on Saturday, June
20, 2020 by live interactive webcast.
This half-day event will feature two segments.
First, a live broadcast of bi-directional TeleRobotic procedures
with physicians navigating catheters from hospitals more than 1700
km apart. In the second half of the symposium, panelists will
discuss current TeleRobotic capabilities and brainstorm practical
ways to advance the missions of the council: to improve patient
care, expand access to high-quality therapy, and enhance physician
education, safety, and efficiency with TeleRobotic Surgery.
In addition, it was announced today the
formation of the TeleRobotic Surgery Leadership Council to advance
remote support, collaboration and procedures in the operating
theater. The mission of the council is described in greater detail
at www.TeleRoboticSurgery.io.
During the webcast, the live TeleRobotic
procedures will be performed by Prof. Pedro Adragão, from Hospital
Da Luz in Lisbon, and Prof. Carlo Pappone, from Policlinico San
Donato in Milan. Panelists at the symposium include:
- J. David Burkhardt, M.D. – St. David’s Medical Center
- Jim Cheung, M.D. – Weill Cornell Medical Center
- Joseph Dell’Orfano, M.D. – St. Francis Hospital
- Benjamin D’Souza, M.D. – Penn Presbyterian Medical
Center
- Gabriel Latcu, M.D. – Princess Grace Hospital
- J. Peter Weiss, M.D. – Banner University Medical
Center
- Joseph Wu, M.D. – Kaiser Permanente Los Angeles
- Matthew Dare – St. David’s Medical Center
- Joe Mullings – The Mullings Group
“Telemedicine will play an increasingly
important role in the operating rooms of the future,” said David
Fischel, Stereotaxis Chairman and CEO. “Increased connectivity and
collaboration beyond geographical limitations will contribute to
improved care, expanded access to care, and accelerated knowledge
sharing. Robotics plays a central role in digitizing the operating
room and we are excited to be pioneering these capabilities in
partnership with leading physicians and hospitals.”
Registration for the event is open to
physicians, healthcare professionals, industry partners, and
technology leaders.
Date: |
Saturday, June 20, 2020 |
Times: |
10:00 ET / 16:00 CET Live Procedure Broadcast |
|
11:30 ET / 17:30 CET Panel Symposium |
Registration for the event and access to the full agenda
available at www.TeleRoboticSurgery.io
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Sep 2023 to Sep 2024